カテゴリ： GlobalData, イギリス, 企業調査

Horizon Discovery Group Plc (HZD)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Horizon Discovery Group Plc (HZD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C7949
◆発行会社（調査会社）：GlobalData
◆発行日：2018年10月
◆ページ数：110
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：イギリス
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Horizon Discovery Group Plc (Horizon Discovery) is a life science company that discovers and develops genetically-modified cell lines using a proprietary translational genomics platform. The company offers products such as cell lines, reference standards and in vivo models. It also offers services such as CRISPR screening, combination screening, in vivo assay services and cell-based assays, among others. Horizon Discovery offers its products and services to genomic research organizations, pharmaceutical, biotechnology and diagnostic companies and academic research centers for the formulation of customized medicines. The company has operations in the UK and the US. Horizon Discovery is headquartered in Cambridge, the UK.

Horizon Discovery Group Plc (HZD) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Horizon Discovery Group Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Horizon Discovery Group Plc, Medical Devices Deals, 2012 to YTD 2018 12
Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deal Details 17
Asset Purchase 17
Horizon Discovery Completes Acquisition of Combination High Throughput Screening from Zalicus 17
Venture Financing 18
Horizon Discovery Raises US$10.5 Million In Final Closing Of Series C Financing 18
Private Equity 20
ValueAct Capital Acquires Additional Stake in Horizon Discovery Group from Woodford Investment Management 20
Partnerships 21
Horizon Discovery Enters into Licensing Agreement for Transposon Based Technology Platform 21
Horizon Discovery Enters Into Licensing Agreement With ATCC 22
Celyad Enters into Agreement with Horizon Discovery 23
Horizon Discovery Enters into Partnership 24
Horizon Discovery Enters into Co-Development Agreement with Roche Diagnostics 25
Horizon Discovery Enters into Research Agreement with Solentim 26
Horizon Discovery Enters into Agreement with Fulcrum Therapeutics 27
Horizon Discovery Enters into Agreement with Ubiquigent 28
Horizon Discovery Forms Joint Venture with Centauri Therapeutics 29
Horizon Discovery Partners with Axol Bioscience 30
Horizon Discovery Enters into Agreement with Swift Biosciences 31
Horizon Discovery Enters into Research Agreement with Redx Pharma 32
Horizon Discovery Enters into Co-Development Agreement with DefiniGEN 33
CareDx Enters into Co-Development Agreement with Horizon Discovery 34
Horizon Discovery Enters into Agreement with Thermo Fisher Scientific 35
Horizon Discovery Enters Into Marketing Agreement With Thermo Fisher 36
Horizon Discovery Enters into Distribution Agreement with Haplogen Genomics 37
Horizon Discovery Enters into Development and Commercialization Agreement with Otsuka Pharma 38
Horizon Discovery Enters Into Co-Development Agreement With Desktop Genetics 39
Crown Bioscience Enters Into Agreement With Horizon Discovery To Develop In Vivo Models For Drug Discovery 40
Horizon Discovery Enters Into R&D Agreement With UCL Institute of Neurology For rAAV-mediated Genome Editing 41
Crown Bioscience Enters Into Co-Development Agreement With Horizon Discovery 42
Horizon Discovery Enters Into Agreement With Domainex To Support Oncology Program 43
Horizon Discovery Enters Into Co-Development Agreement With Bayer Pharma For Human Isogenic Cell Lines 44
Horizon Discovery Enters Into Co-Development Agreement With H3 Biomedicine 45
Licensing Agreements 46
Cytovance Biologics Enters into Licensing Agreement with Horizon Discovery 46
Horizon Discovery Enters into Licensing Agreement with US Immuno-Oncology Company 47
ATUM Enters into Licensing Agreement with Horizon Discovery 48
Horizon Discovery Enters into Licensing Agreement with ATUM 49
Horizon Discovery Group Enters into Licensing Agreement with AmplyCell 50
Horizon Discovery Enters into Licensing Agreement with Wistar Institute 51
Horizon Discovery Enters into Licensing Agreement with Servier Lab 52
LakePharma Enters into Licensing Agreement with Horizon Discovery 53
Abcam Enters into Licensing Agreement with Horizon Discovery 54
Horizon Discovery Extends Licensing Agreement with ERS Genomics 55
Horizon Discovery And AstraZeneca Enter Into Licensing Agreement To Develop Cancer Therapies 56
Horizon Discovery Group Enters into Licensing Agreement 58
Horizon Discovery Enters into Licensing Agreement with ProteoNic 59
Horizon Discovery Enters into Licensing Agreement with Stanford University 60
Horizon Discovery Enters into Licensing Agreement with Broad Institute for Crispr Gene Editing System 61
Horizon Discovery Enters Into Licensing Agreement With AstraZeneca 62
Horizon Discovery Enters Into Licensing Agreement With Harvard University For Crispr Gene Editing Technology 63
Sigma-Aldrich Enters Into Licensing Agreement With Horizon Discovery For CompoZr Zinc Finger Nuclease Technology 64
NIH Center for Regenerative Medicine Enters Into Licensing Agreement With Horizon Discovery For Genesis Technology 65
Horizon Discovery Enters Into Licensing Agreement With Rosalind Franklin University of Medicine and Science 66
Equity Offering 67
Horizon Discovery Raises USD104.6 million in Private Placement of Shares 67
Horizon Discovery Raises USD38.5 Million in Private Placement of Shares 68
Horizon Discovery Completes IPO For US$66.7 Million 69
Acquisition 71
Horizon Discovery Acquires GE Healthcare Dharmacon from General Electric for USD85 Million 71
Horizon Discovery Acquires Haplogen Genomics for USD15 Million 73
Horizon Discovery Acquires Sage Labs for USD48 Million 74
Horizon Discovery Group Plc – Key Competitors 75
Horizon Discovery Group Plc – Key Employees 76
Horizon Discovery Group Plc – Locations And Subsidiaries 77
Head Office 77
Other Locations & Subsidiaries 77
Joint Venture 78
Recent Developments 79
Financial Announcements 79
Sep 17, 2018: HORIZON DISCOVERY GROUP announce interim results for the six months ended 30 June 2018 79
May 08, 2018: Horizon Discovery Group: Preliminary Results for the Year Ended 31 December 2017 84
Sep 26, 2017: Horizon Discovery Group: Interim Results For The Six Months Ended 30 June 2017 85
May 30, 2017: Horizon Discovery Group: Preliminary Results for the Year Ended 31 December 2016 91
Corporate Communications 92
May 17, 2018: Horizon Discovery: Board Change 92
May 08, 2018: Horizon Discovery appoints Terry Pizzie as Chief Executive Officer 93
Mar 02, 2018: Horizon Discovery Group: Board Change 94
Feb 20, 2018: Horizon Discovery Announces Leadership Changes 95
Legal and Regulatory 96
Jul 03, 2017: Horizon Discovery announces inclusion of its Reference Standards in successful FDA approval of an oncology companion diagnostic test with leading next generation sequencing company 96
Government and Public Interest 97
Jul 17, 2017: Sphere Fluidics and Partners Win Major InnovateUK Grant to Develop the World’s First Desktop Genome Editing System 97
May 22, 2017: Horizon Discovery Announces New Gene Editing Technology Platform for Research and Therapeutic Applications 98
Product News 99
Nov 14, 2017: Horizon Discovery’s Dharmacon introduces Edit-R CRISPRa reagent platform for genome-wide CRISPR activation 99
Aug 01, 2017: Horizon Discovery announces release of high quality, well annotated CHO genome sequence to drive innovation in bioproduction 100
May 26, 2017: Horizon Discovery introduces four BRAF resistant melanoma PDX models 102
Mar 26, 2018: Horizon Discovery introduces whole human genome arrayed libraries to support CRISPR activation screening 103
Other Significant Developments 104
Sep 14, 2018: Horizon Discovery Edit-R crRNA libraries adopted by AstraZeneca as part of its functional genomics discovery platform 104
Mar 21, 2018: Horizon Discovery’s Bioproduction cell line used as part of a successful drug (IND) filing 105
Sep 18, 2017: Horizon Discovery announces launch of Genome-Wide CRISPRi and CRISPRa Screening Services 106
May 09, 2017: Horizon Discovery Announces Update on its Immuno-Oncology Platform including Strong Uptake of Product and Service Offerings 107
Jan 24, 2017: Horizon Discovery Group: Trading Update 108
Jan 13, 2017: International Trade Minister Greg Hands visits fast-growing Cambridge life sciences company 109
Appendix 110
Methodology 110
About GlobalData 110
Contact Us 110
Disclaimer 110

List of Tables
Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Horizon Discovery Group Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Horizon Discovery Group Plc, Deals By Therapy Area, 2012 to YTD 2018 11
Horizon Discovery Group Plc, Medical Devices Deals, 2012 to YTD 2018 12
Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Horizon Discovery Completes Acquisition of Combination High Throughput Screening from Zalicus 17
Horizon Discovery Raises US$10.5 Million In Final Closing Of Series C Financing 18
ValueAct Capital Acquires Additional Stake in Horizon Discovery Group from Woodford Investment Management 20
Horizon Discovery Enters into Licensing Agreement for Transposon Based Technology Platform 21
Horizon Discovery Enters Into Licensing Agreement With ATCC 22
Celyad Enters into Agreement with Horizon Discovery 23
Horizon Discovery Enters into Partnership 24
Horizon Discovery Enters into Co-Development Agreement with Roche Diagnostics 25
Horizon Discovery Enters into Research Agreement with Solentim 26
Horizon Discovery Enters into Agreement with Fulcrum Therapeutics 27
Horizon Discovery Enters into Agreement with Ubiquigent 28
Horizon Discovery Forms Joint Venture with Centauri Therapeutics 29
Horizon Discovery Partners with Axol Bioscience 30
Horizon Discovery Enters into Agreement with Swift Biosciences 31
Horizon Discovery Enters into Research Agreement with Redx Pharma 32
Horizon Discovery Enters into Co-Development Agreement with DefiniGEN 33
CareDx Enters into Co-Development Agreement with Horizon Discovery 34
Horizon Discovery Enters into Agreement with Thermo Fisher Scientific 35
Horizon Discovery Enters Into Marketing Agreement With Thermo Fisher 36
Horizon Discovery Enters into Distribution Agreement with Haplogen Genomics 37
Horizon Discovery Enters into Development and Commercialization Agreement with Otsuka Pharma 38
Horizon Discovery Enters Into Co-Development Agreement With Desktop Genetics 39
Crown Bioscience Enters Into Agreement With Horizon Discovery To Develop In Vivo Models For Drug Discovery 40
Horizon Discovery Enters Into R&D Agreement With UCL Institute of Neurology For rAAV-mediated Genome Editing 41
Crown Bioscience Enters Into Co-Development Agreement With Horizon Discovery 42
Horizon Discovery Enters Into Agreement With Domainex To Support Oncology Program 43
Horizon Discovery Enters Into Co-Development Agreement With Bayer Pharma For Human Isogenic Cell Lines 44
Horizon Discovery Enters Into Co-Development Agreement With H3 Biomedicine 45
Cytovance Biologics Enters into Licensing Agreement with Horizon Discovery 46
Horizon Discovery Enters into Licensing Agreement with US Immuno-Oncology Company 47
ATUM Enters into Licensing Agreement with Horizon Discovery 48
Horizon Discovery Enters into Licensing Agreement with ATUM 49
Horizon Discovery Group Enters into Licensing Agreement with AmplyCell 50
Horizon Discovery Enters into Licensing Agreement with Wistar Institute 51
Horizon Discovery Enters into Licensing Agreement with Servier Lab 52
LakePharma Enters into Licensing Agreement with Horizon Discovery 53
Abcam Enters into Licensing Agreement with Horizon Discovery 54
Horizon Discovery Extends Licensing Agreement with ERS Genomics 55
Horizon Discovery And AstraZeneca Enter Into Licensing Agreement To Develop Cancer Therapies 56
Horizon Discovery Group Enters into Licensing Agreement 58
Horizon Discovery Enters into Licensing Agreement with ProteoNic 59
Horizon Discovery Enters into Licensing Agreement with Stanford University 60
Horizon Discovery Enters into Licensing Agreement with Broad Institute for Crispr Gene Editing System 61
Horizon Discovery Enters Into Licensing Agreement With AstraZeneca 62
Horizon Discovery Enters Into Licensing Agreement With Harvard University For Crispr Gene Editing Technology 63
Sigma-Aldrich Enters Into Licensing Agreement With Horizon Discovery For CompoZr Zinc Finger Nuclease Technology 64
NIH Center for Regenerative Medicine Enters Into Licensing Agreement With Horizon Discovery For Genesis Technology 65
Horizon Discovery Enters Into Licensing Agreement With Rosalind Franklin University of Medicine and Science 66
Horizon Discovery Raises USD104.6 million in Private Placement of Shares 67
Horizon Discovery Raises USD38.5 Million in Private Placement of Shares 68
Horizon Discovery Completes IPO For US$66.7 Million 69
Horizon Discovery Acquires GE Healthcare Dharmacon from General Electric for USD85 Million 71
Horizon Discovery Acquires Haplogen Genomics for USD15 Million 73
Horizon Discovery Acquires Sage Labs for USD48 Million 74
Horizon Discovery Group Plc, Key Competitors 75
Horizon Discovery Group Plc, Key Employees 76
Horizon Discovery Group Plc, Other Locations 77
Horizon Discovery Group Plc, Subsidiaries 77
Horizon Discovery Group Plc, Joint Venture 78

List of Figures
Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9
Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Horizon Discovery Group Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Horizon Discovery Group Plc, Medical Devices Deals, 2012 to YTD 2018 12

★海外企業調査レポート[Horizon Discovery Group Plc (HZD)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Oil & Gas Development Co Ltd (OGDC)：企業の財務・戦略的SWOT分析
    Oil & Gas Development Co Ltd (OGDC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Sumitomo Precision Products Co Ltd
    Sumitomo Precision Products Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Sumitomo Precision Products Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Organo Corporation：企業の戦略・SWOT・財務情報
    Organo Corporation - Strategy, SWOT and Corporate Finance Report Summary Organo Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Electric Power Industry of Serbia：企業の戦略的SWOT分析
    Electric Power Industry of Serbia - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • Enterprise Therapeutics Ltd：製薬・医療：M&Aディール及び事業提携情報
    Summary Enterprise Therapeutics Ltd (Enterprise Therapeutics) is a drug discovery company that offers research and development of novel therapies for the treatment of respiratory diseases. The company also identifies novel targets and compounds which reduces the mucus production. It provides therape …
  • CareDx Inc (CDNA)：製薬・医療：M&Aディール及び事業提携情報
    Summary CareDx Inc (CareDx), formerly XDx Inc, is a commercial stage molecular diagnostics company that develops, markets, and delivers diagnostic surveillance solutions. The company offers commercialized testing solution, the AlloMap heart transplant molecular test, is a noninvasive blood test used …
  • RH Petrogas Ltd (T13)：企業の財務・戦略的SWOT分析
    Summary RH Petrogas Ltd (RH Petrogas) is an oil and gas company that explores, develops and produces oil and gas resources. The company’s properties include FUYU 1 block, Basin and Island PSC, and SK331 PSC. Its FUYU 1 block property is located in south-east of the Fuyu oilfield in the Jilin provinc …
  • Flexera Software LLC：企業の戦略的SWOT分析
    Flexera Software LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Eternygen GmbH：製薬・医療：M&Aディール及び事業提携情報
    Summary Eternygen GmbH (Eternygen) is a drug discovery company that offers research and development of innovative drugs for dietary-related metabolic diseases. The company’s product development portfolio includes novel small molecule inhibitors, developed against the sodium coupled citrate transport …
  • KT&G Corp：企業の戦略・SWOT・財務情報
    KT&G Corp - Strategy, SWOT and Corporate Finance Report Summary KT&G Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Entertainment One Ltd.：企業のM&A・事業提携・投資動向
    Entertainment One Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Entertainment One Ltd. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions …
  • Abbott Diabetes Care Inc-医療機器分野：企業M&A・提携分析
    Summary Abbott Diabetes Care Inc (ADC), formerly TheraSense Inc, a subsidiary of Abbott Laboratories, is a medical device company that discovers, develops, manufactures, and markets pharmaceuticals and medical products for personal use and hospital use. The company’s products include glucose monitor …
  • Electro Scientific Industries Inc (ESIO)：企業の財務・戦略的SWOT分析
    Summary Electro Scientific Industries Inc (ESI) is a brand of MKS Instruments Equipment & Solutions Division, which offers laser-based manufacturing solutions. The company offers products such as flex interconnect, circuit packaging, high density interconnect, automation, scribbing and grooving, mem …
  • Inivata Ltd：製品パイプライン分析
    Summary Inivata Ltd (Inivata) is a clinical cancer genomics company that utilizes the precision of circulating tumor DNA analysis to improve personalized healthcare in oncology. The company uses liquid biopsy platform, to identify and characterize ctDNA through a non-invasive blood test. Its liquid …
  • Health Care Service Corporation：企業の戦略・SWOT・財務分析
    Health Care Service Corporation - Strategy, SWOT and Corporate Finance Report Summary Health Care Service Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Keepmoat Ltd：企業の戦略的SWOT分析
    Keepmoat Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • SandRidge Energy Inc (SD)：企業の財務・戦略的SWOT分析
    SandRidge Energy Inc (SD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Green Cross Cell Corp (031390)：企業の財務・戦略的SWOT分析
    Green Cross Cell Corp (031390) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Smith & Nephew Plc (SN.)-製薬・医療分野：企業M&A・提携分析
    Summary Smith & Nephew Plc (Smith & Nephew) develops, manufactures and markets medical devices for use in orthopedic reconstruction, orthopedic trauma and clinical therapies, sports medicines and advanced wound management. The company offers its products in various categories including Sports Medici …
  • Samyang Holdings Corp (000070)：企業の財務・戦略的SWOT分析
    Summary Samyang Holdings Corp (Samyang) is a holding company engaged in the development and manufacture of food, pharmaceutical and chemical products. The company produces chemicals such as terephthalic acid, engineering plastics, organic chemicals, resins and other specialty chemicals; food materia …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆